GLP-1 medicines have become a major part of conversations about weight, blood sugar, and metabolic health. That visibility has created opportunity: some people who once felt shut out of care are now asking better questions about diabetes, obesity, and long-term risk. It has also created a problem. A medication can be presented online as if it were the entire plan.
It is not.
A recent Medical Daily article makes an important point: a prescription should follow a real clinical evaluation, not a brief questionnaire paired with a credit-card screen. That principle applies whether care takes place in a clinic or by telehealth. Virtual care can be convenient and clinically appropriate; the standard should be the quality and continuity of the evaluation, not the location of the video visit.
Start with the right question: Is this medicine appropriate for this person?
Responsible prescribing begins by clarifying the goal. Is the medication being considered for type 2 diabetes, chronic weight management, cardiovascular risk, or another approved indication? What has already been tried? What does the person hope will change—not only on the scale or laboratory report, but in energy, mobility, eating patterns, sleep, and quality of life?
A clinician also needs the context that an algorithm or a single self-reported measurement may miss. That includes current medications and supplements, medical history, family history, pregnancy plans where relevant, symptoms that could signal gastrointestinal disease, and the person’s experience with food and appetite. The prescribing information for a specific product is one essential reference because indications, warnings, contraindications, and dosing instructions are product-specific. Readers can review the current FDA-approved Wegovy prescribing information, but should discuss how it applies to them with their prescriber.
That is not needless bureaucracy. GLP-1 medicines can affect appetite and gastric emptying, and they may require extra care when a person uses other glucose-lowering medications. A patient’s history can also change the risk-benefit conversation. Good care makes space for that conversation before the first prescription—not after an unexpected side effect or a refill problem.
Telehealth can be thorough. It should not be shallow.
Telehealth may make follow-up more accessible for people who live far from specialty care, have transportation barriers, or need frequent touchpoints. The format can support coaching, medication review, device data, nutrition education, and monitoring. But convenience is not a substitute for clinical accountability.
A quality virtual program should make it clear who is prescribing, how the clinician is licensed, how medical history is reviewed, how follow-up will occur, and what happens if the patient develops a concerning symptom. It should also have a transparent plan for referrals and in-person care when necessary.
The practical questions are simple. Will a clinician review the full medication list? Will relevant baseline data be considered? Who answers questions between visits? Is there a plan to preserve nutrition, hydration, and strength as appetite changes? How will the program address a plateau, an adverse effect, a coverage interruption, or a desire to discontinue treatment?
An informed patient should be able to ask those questions without being made to feel difficult. They are part of safer care.
Know what is being dispensed
It is also reasonable to ask whether a prescription is for an FDA-approved medicine or a compounded preparation, and which pharmacy will dispense it. The FDA warns that unapproved versions of GLP-1 medicines do not undergo the agency’s review for safety, effectiveness, or quality before marketing. The agency advises patients to obtain prescriptions from their clinicians and to fill them through state-licensed pharmacies.
This is not a reason to make broad assumptions about every patient or every pharmacy. It is a reason to insist on clarity. A person considering treatment deserves to know what product they are receiving, how it should be stored and used, who will provide instructions, and where to seek help if something does not look right.
Medication works best when it is connected to care
The most constructive GLP-1 conversation is neither “medication is the answer” nor “medication is a failure.” For some people, medication is an appropriate and valuable part of a treatment plan. For others, it may not be appropriate, accessible, tolerated, or sufficient on its own.
In either case, long-term metabolic health is built in the day-to-day environment. Protein and fiber intake, enjoyable movement, resistance or strength work when appropriate, sleep, stress, relationships, financial access to food, and realistic routines all matter. So does recognizing that appetite changes can complicate nutrition. A lower appetite is not automatically better nutrition, and rapid weight change does not automatically equal better health.
A responsible care plan helps a person make changes they can live with. It has room for medication when clinically indicated, but it does not treat the prescription as a replacement for the rest of health care.
A useful standard: A GLP-1 prescription should come with a plan for assessment, education, monitoring, nutrition, movement, and follow-up—not simply a checkout page.
The Diabetes Reversal Group perspective
At Diabetes Reversal Group, we believe type 2 diabetes deserves more than a choice between “take a medication” and “do it all yourself.” Holistic care addresses food quality, movement, sleep, stress, support systems, access, monitoring, and medications when they are clinically appropriate. Our goal is not to turn anyone away from effective treatment. It is to make sure treatment supports lasting metabolic health rather than becoming the only thing we talk about.
By: Dr. Jeffrey Hockings, CEO & Founder & Kristine Burke, MD, Chief Medical Officer
Do not start, stop, or change a prescribed medication based on an advertisement, social post, or general article. Work with the clinician who knows your health history and treatment plan.